These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy. Kirshenbaum JM; Kloner RF; McGowan N; Antman EM J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259 [TBL] [Abstract][Full Text] [Related]
3. Effects of esmolol on patients with left ventricular dysfunction. Iskandrian AS; Bemis CE; Hakki AH; Panidis I; Heo J; Toole JG; Hua TA; Allin D; Kane-Marsch S J Am Coll Cardiol; 1986 Jul; 8(1):225-31. PubMed ID: 2872244 [TBL] [Abstract][Full Text] [Related]
4. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082 [TBL] [Abstract][Full Text] [Related]
5. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker. Strom J; Josephson M; Frishman WH; Singh B; Heilbrunn S; Osterle S; Turlapaty P; Viray R; Coe J; Bell V J Clin Pharmacol; 1988 Mar; 28(3):276-82. PubMed ID: 2896204 [TBL] [Abstract][Full Text] [Related]
7. [The hemodynamic effects of a treatment with beta-receptor blockers during coronary surgery. A comparison between acebutolol and esmolol]. Kling D; Boldt J; Zickmann B; Dapper F; Hempelmann G Anaesthesist; 1990 May; 39(5):264-8. PubMed ID: 1972611 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease. Mitrovic V; Oehm E; Thormann J; Pitschner H; Haberbosch W Clin Cardiol; 1998 Jul; 21(7):492-502. PubMed ID: 9669058 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children. Cuneo BF; Zales VR; Blahunka PC; Benson DW Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803 [TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous infusion of esmolol and propranolol on biventricular performance at rest and during exercise as assessed by quantitative radionuclide angiography. Iskandrian AS; Hakki AH; Laddu A; Steck J; Saunders R; Kane-Marsch S; Morganroth J Am J Cardiol; 1985 May; 55(11):1287-92. PubMed ID: 3993558 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and antiarrhythmic effects of esmolol in children. Trippel DL; Wiest DB; Gillette PC J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729 [TBL] [Abstract][Full Text] [Related]
17. Effects of esmolol on cardiac function: evaluation by noninvasive techniques. Iskandrian AS; Hakki AH; Laddu A Am J Cardiol; 1985 Oct; 56(11):27F-32F. PubMed ID: 2864845 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study. Levy B; Fritz C; Piona C; Duarte K; Morelli A; Guerci P; Kimmoun A; Girerd N Crit Care; 2021 Jan; 25(1):21. PubMed ID: 33413583 [TBL] [Abstract][Full Text] [Related]
19. Esmolol and the adrenergic response to perioperative stimuli. Murthy VS; Hwang TF; Sandage BW; Laddu AR J Clin Pharmacol; 1986 Mar; 26(S1):A27-A35. PubMed ID: 2870083 [TBL] [Abstract][Full Text] [Related]
20. The use of esmolol in whole-body hyperthermia: cardiovascular effects. Berry JM; Michalsen A; Nagle V; Bull JM Int J Hyperthermia; 1997; 13(3):261-8. PubMed ID: 9222810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]